18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-…
この記事を読む
「論文メモ」の記事一覧 12ページ
この記事を読む
ペムブロリズマブ3週から6週間隔への変更でirAEが増える可能性
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With…
この記事を読む
小細胞肺癌に対する免疫療法の実地データ
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer Shira Sagie et al.lung Cancer …
この記事を読む
ヒスパニック系におけるオシメルチニブの耐性機序
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRE…
この記事を読む
低分化型腺癌と腫瘍微小環境との関連
Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic t…
この記事を読む
ALK/ROS1陽性は血栓塞栓症のリスクが高い
Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study. Lin M e…
この記事を読む
KEYNOTE-091、術後補助化学療法後のペムブロリズマブ、解釈が難しい
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-ⅢA non-small-cell lung cancer (PEARLS/…
この記事を読む
オシメルチニブ＋ベバシズマブは喫煙者向き？
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCL…
この記事を読む
定位放射線治療：一回照射の注意点
Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. Kang TM et al.Lung Cancer. 2…
この記事を読む
喫煙者のEGFR遺伝子変異陽性にはベバシズマブ上乗せが効果的？
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: T…